SCHEMBL408250

SCHEMBL408250

CCCCCc1cc2c3ccccc3c(CCCCC)cc2c2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 2/20 0.48
TLR8 Q9NR97 6/20 0.45
MAPT P10636 4/20 0.43
CYP3A4 P08684 2/20 0.43
MEN1 O00255 1/20 0.43
TP53 P04637 1/20 0.43
ALOX5 P09917 1/20 0.43
TYR P14679 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CTSV O60911 1/20 0.42
CTSL P07711 1/20 0.42
KDM4E B2RXH2 1/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3677393 0.85 LIPG (0.53) LIPGTLR8MAPTCYP3A4MEN1
SCHEMBL30537736 0.83 LIPG (0.57) LIPGMAPTCYP3A4MEN1TP53
SCHEMBL11779245 0.83 LIPG (0.57) LIPGMAPTCYP3A4MEN1TP53
SCHEMBL324540 0.82 ALOX5 (0.47) LIPGTLR8MAPTCYP3A4MEN1
SCHEMBL3096941 0.80 TLR8 (0.50) LIPGTLR8MAPTCYP3A4MEN1
SCHEMBL7713514 0.78 HTT (0.50) LIPGMAPTCYP3A4MEN1TP53
SCHEMBL8823285 0.78 CNR2 (0.48) LIPGTLR8MAPTCYP3A4TYR
SCHEMBL30537734 0.78 CNR2 (0.48) LIPGTLR8MAPTCYP3A4TYR
SCHEMBL3674865 0.78 LIPG (0.52) LIPGMAPTCYP3A4MEN1TP53
SCHEMBL170762 0.78 LIPG (0.52) LIPGTLR8ALOX5KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408728-B1 NOVEL CHRYSENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE HAVING THE COMPOUND CANON KK (JP) 2016-05-25 EP disclosed
US-8557401-B2 Chrysene compound and organic light-emitting device having the compound CANON KABUSHIKI KAISHA (JP) 2013-10-15 US disclosed
EP-2408728-A1 NOVEL CHRYSENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE HAVING THE COMPOUND Canon Kabushiki Kaisha (JP) 2012-01-25 EP disclosed
US-20110279025-A1 NOVEL CHRYSENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE HAVING THE COMPOUND CANON KABUSHIKI KAISHA (JP) 2011-11-17 US disclosed
WO-2010107037-A1 NOVEL CHRYSENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE HAVING THE COMPOUND CANON KABUSHIKI KAISHA (JP) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110279025-A1 NOVEL CHRYSENE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE HAVING THE COMPOUND AHR, CRY2, ARL1 LIPG 4668/4885TLR8 3318/4885MAPT 1608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.